No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CRH240621C62500
- 22.00
- 0.000.00%
15min DelayTrading Jun 18 15:59 ET
0.00High0.00Low
0.00Open22.00Pre Close0 Volume10 Open Interest62.50Strike Price0.00Turnover200.82%IV8.50%PremiumJun 21, 2024Expiry Date15.38Intrinsic Value100Multiplier1DDays to Expiry6.62Extrinsic Value100Contract SizeAmericanOptions Type0.9448Delta0.0108Gamma3.54Leverage Ratio-0.2503Theta0.0026Rho3.34Eff Leverage0.0057Vega
Intraday
- 5D
- Daily
No Data
News
CRH Started at Overweight at Stephens on Healthy Demand Backdrop
Express News | CRH PLC : Stephens Initiates Coverage With Overweight Rating; Target Price $95
CRH Initiated at Overweight by Stephens & Co.
CRH Initiated at Overweight by Stephens & Co.
Express News | Stephens & Co. Initiates Coverage On CRH With Overweight Rating, Announces Price Target of $95
CRH Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 20.97% Stephens & Co. → $95 Initiates Coverage On → Overweight 05/14/2024 40.07% RBC Capital →
Stephens Initiates CRH PLC(CRH.US) With Buy Rating, Announces Target Price $95
Stephens analyst Trey Grooms initiates coverage on $CRH PLC(CRH.US)$ with a buy rating, and sets the target price at $95.According to TipRanks data, the analyst has a success rate of 56.5% and a total
Comments
G'day, mooers! Check out the latest news on today's stock market!
• US major indexs fell
• ASX 200 rises by broad buying; ANZ sells stake in Malaysian bank
• Stocks to watch: Telix Pharmaceuticals, Adbri, Pro Medicus
Wall Street Summary
Indexs fell Thursday after harsh earnings reactions. Overall, there was more green than red out there, but by the numbers after the close, the $S&P 500 Index(.SPX.US$ traded -0.60%,...
• US major indexs fell
• ASX 200 rises by broad buying; ANZ sells stake in Malaysian bank
• Stocks to watch: Telix Pharmaceuticals, Adbri, Pro Medicus
Wall Street Summary
Indexs fell Thursday after harsh earnings reactions. Overall, there was more green than red out there, but by the numbers after the close, the $S&P 500 Index(.SPX.US$ traded -0.60%,...
2
CRH's dividend is seen as sustainable, backed by profit and cash flow. Its growing earnings and low payout ratios hint at a promising long-term dividend stock. The firm's consistent dividend and earnings growth show a commitment to rewarding shareholders.
1
Despite lower than expected Q4 numbers, investors are not worried due to the company's positive outlook for 2024, driven by significant infrastructure investment and re-industrialization activity across key markets in North America and Europe.
The strong EPS growth and insider buying at CRH indicate a positive outlook for the company. The growth rate and insider activity suggest that the company could be a good investment opportunity.
1
The market's view of CRH has improved over the last five years, likely due to consistent earnings growth. Recent insider buying and strong share price momentum suggest potential investment opportunities.
Read more